Caspian Therapeutics, Inc. ("Caspian") and Kura Oncology, Inc. (Nasdaq: KURA, "Kura") plan to outline the development strategy for KO-7246, Caspian’s selective, oral menin inhibitor designed for diabetes and other chronic metabolic diseases, in a webcast later today. Management from both companies will discuss the rationale for creating Caspian, the findings presented at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, and KO-7246’s path toward clinical proof of concept.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.